Clinicopathologic and prognosis of 30 patients with FH-deficient renal cell carcinoma: a single-center retrospective study

Clinicopathologic and prognosis of 30 patients with FH-deficient renal cell carcinoma: a single-center retrospective study

Abstract Background FH-Deficient Renal Cell Carcinoma (FH-RCC) is a rare, aggressive cancer with poor prognosis and treatment challenges. Immunohistochemical (IHC), including PD-1, PD-L1, PD-L2, and CTLA-4, play a key role in survival outcomes and therapeutic decisions, highlighting the need to eval...

Full description

Saved in:

Bibliographic Details
Main Authors:	Junjie Bai, Jianjia Huang, Yushi Ye, Jun Lin, Yahui Wen, Zicheng Cai, Peihuang Chen, Tong Shangguan, Gaoyu Zou, Qianyi Qiu, Ru Chen, Rong Liu, Weizhong Cai, Shaoxing Zhu, Jianhui Chen, Xiaoyan Li
Format:	Article
Language:	English
Published:	BMC 2025-07-01
Series:	BMC Cancer
Subjects:	FH-Deficient renal cell carcinoma Immunohistochemical Programmed death ligand-1 (PD-L1) Programmed death ligand-2 (PD-L2)
Online Access:	https://doi.org/10.1186/s12885-025-14562-6
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck
by: Yu. V. Kostalanova, et al.
Published: (2020-11-01)

Influence of programmed death ligand 1 (PD-L1) knockout on gut microbiota in experimental autoimmune uveitis
by: Junxiang Gu, et al.
Published: (2025-05-01)

PD-L1 on Circulating Tumor Cells Indicates Poor Prognosis in Breast Cancer
by: Xue-fei Wang, et al.
Published: (2022-11-01)

Development and Validation of a Biolayer Interferometry Method for Determination of Human Anti-PD-1 Monoclonal Antibody Concentration in Cynomolgus Serum
by: K. V. Ulyanova, et al.
Published: (2020-12-01)

The features of PD-L1 expression in tumor stromal cells, peritumoral microvessels and isolated clusters of tumor cells in breast cancer tissue and their correlation with clinical and morphological characteristics of breast cancer
by: E. Yu. Zubareva, et al.
Published: (2023-11-01)

Immune checkpoint inhibitors in patients with advanced gastric cancer: a multi-institutional retrospective real-world study
by: Anastasia Rays, et al.
Published: (2025-03-01)

Accessing utility of immunohistochemistry, PD-L1 correlation with stage of cancer and EGFR mutation with disease survival in primary lung carcinoma
by: Kartavya Kumar Verma, et al.
Published: (2025-06-01)

Case Report: Long-term response control in a patient with metastatic gastric squamous cell carcinoma treated with nivolumab and chemoradiotherapy
by: Yu-ying Lei, et al.
Published: (2025-08-01)

Programmed death ligand 1 (PD-L1) expression in gastric cancer: literature review
by: T. N. Sotnikova, et al.
Published: (2023-07-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression
by: Wei-Wen Sung, et al.
Published: (2022-01-01)

Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA
by: Mushi Chen, et al.
Published: (2019-12-01)

Recent advances in the mechanisms of PD-L1 expression in gastric cancer: a review
by: Peifeng Chen, et al.
Published: (2025-03-01)

Transcriptional, growth factors, components of the AKT/mTOR signaling pathway, receptors and ligands of programmed cell death expression in melanoma
by: K. V. Nikulnikov, et al.
Published: (2024-04-01)

Risk scoring model for lung adenocarcinoma based on PD-L1 related signature reveals prognostic predictability and correlation with tumor immune microenvironment genes was constructed
by: Meng Li-Fei, et al.
Published: (2025-06-01)

Evaluation of polymorphism in BCL-2, PD-1, and PD-L1 genes in myelodysplastic neoplasms
by: Bartłomiej Kuszczak, et al.
Published: (2025-01-01)

Expression of PD-L1, AR, and P53 in urothelial carcinoma and their correlation with clinical prognosis
by: ZHOU Xiaodie, Qi Rongxin, WANG Xuan, YU Bo, WANG Jianjun, SHI Qunli, RAO Qiu, BAO Wei
Published: (2025-06-01)

Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer
by: Jing Liu, et al.
Published: (2025-07-01)

Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma
by: Yu-Yun Shao, et al.
Published: (2025-04-01)

PD-L1 expression and its association with clinicopathological and computed tomography features in surgically resected non-small cell lung cancer: a retrospective cohort study
by: Shiwei Wang, et al.
Published: (2025-07-01)

IRF4 Mediates Immune Evasion to Facilitate EBV Transformation
by: Ling Wang, et al.
Published: (2025-06-01)

Clinical characteristics and comparative analysis of PD-1/PD-L1 inhibitor-induced pituitary dysfunction versus other pituitary disorders
by: Yan Xiao, et al.
Published: (2025-07-01)

Distinct Roles of HHLA2 and PD-L1 in the Immune Cell and Prognosis of Hepatocellular Carcinoma
by: Wang CH, et al.
Published: (2025-07-01)

Repulsive guidance molecules b (RGMb): molecular mechanism, function and role in diseases
by: Jie Zhang, et al.
Published: (2024-01-01)

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends
by: Talaiti Tuergan, et al.
Published: (2025-12-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

Anti-PD-1 antibody enhances homeostatic proliferation–induced antitumor immunity during lymphopenia recovery
by: Zike Yang, et al.
Published: (2025-05-01)

Comparison of programmed death ligand-1 expression in preoperative transbronchial lung biopsy and resected specimens in non-small cell lung cancer
by: Naoko Shigeta, et al.
Published: (2025-04-01)

Sulfafurazole dimers potentiate chemo-immunotherapy of low immunogenic breast cancer by preventing the PD-L1 exosomes secretion
by: Zheng Wang, et al.
Published: (2025-05-01)

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty
by: Meshach Asare-Werehene, et al.
Published: (2025-07-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

CDK2 inhibition sensitizes anthracycline-induced immunogenic cell death and enhances the efficacy of anti-PD-1 therapy
by: Yu Chen, et al.
Published: (2025-06-01)

Changes in soluble PD-L1 levels in patients with advanced non-small cell lung cancer
by: Ta Thang Ba, et al.
Published: (2024-11-01)

Inhibition of PRC1 elicits immunogenic cell death by triggering ROS-dependent ER stress in colorectal cancer via the Wnt/β-catenin signaling pathway
by: Wei Wang, et al.
Published: (2025-08-01)

Development and validation of interpretable machine learning models for predicting AKI risk in patients treated with PD-1/PD-L1: a retrospective study
by: Wentong Liu, et al.
Published: (2025-08-01)

Involvement of the Programmed Death 1/Programmed Death Ligand 1 Pathway in the Immune Microenvironment of Chronic Periapical Lesions
by: Yujin Song, et al.
Published: (2025-08-01)

Theoretical investigation on PD-L1-In-1 for cancer immunotherapy via density functional theory
by: Bijay Sijapati Magar, et al.
Published: (2025-08-01)

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
by: Wenke Li, et al.
Published: (2025-07-01)

Anti‐Angiogenic Agents for Advanced Hepatocellular Carcinoma Induce Liver Atrophy
by: Taijiro Wake, et al.
Published: (2025-08-01)

<i>PD-L1</i> and <i>PD-L2</i> gene expression in human glioblastoma cells resistant to chemo- and radiotherapy
by: A. A. Pinevich, et al.
Published: (2023-06-01)